Cancer Genetics, Inc. (Nasdaq:  CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world.  Its tests target cancers that are difficult to diagnose and predict treatment outcomes.  These cancers include hematological, urogenital and HPV-associated cancers.  It also offers a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies.  Its state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.  It has established strong research collaborations with major cancer centers including Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.  For further information, please see www.cancergenetics.com